1. Home
  2. PBMWW vs CHD Comparison

PBMWW vs CHD Comparison

Compare PBMWW & CHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • CHD
  • Stock Information
  • Founded
  • PBMWW N/A
  • CHD 1846
  • Country
  • PBMWW Canada
  • CHD United States
  • Employees
  • PBMWW 10
  • CHD N/A
  • Industry
  • PBMWW
  • CHD Package Goods/Cosmetics
  • Sector
  • PBMWW
  • CHD Consumer Discretionary
  • Exchange
  • PBMWW Nasdaq
  • CHD Nasdaq
  • Market Cap
  • PBMWW N/A
  • CHD N/A
  • IPO Year
  • PBMWW N/A
  • CHD N/A
  • Fundamental
  • Price
  • PBMWW $0.01
  • CHD $109.05
  • Analyst Decision
  • PBMWW
  • CHD Buy
  • Analyst Count
  • PBMWW 0
  • CHD 21
  • Target Price
  • PBMWW N/A
  • CHD $107.14
  • AVG Volume (30 Days)
  • PBMWW N/A
  • CHD 1.6M
  • Earning Date
  • PBMWW N/A
  • CHD 11-01-2024
  • Dividend Yield
  • PBMWW N/A
  • CHD 1.04%
  • EPS Growth
  • PBMWW N/A
  • CHD 26.23
  • EPS
  • PBMWW N/A
  • CHD 2.23
  • Revenue
  • PBMWW N/A
  • CHD $6,053,100,000.00
  • Revenue This Year
  • PBMWW N/A
  • CHD $4.81
  • Revenue Next Year
  • PBMWW N/A
  • CHD $3.93
  • P/E Ratio
  • PBMWW N/A
  • CHD $48.90
  • Revenue Growth
  • PBMWW N/A
  • CHD 4.80
  • 52 Week Low
  • PBMWW N/A
  • CHD $90.26
  • 52 Week High
  • PBMWW N/A
  • CHD $110.31
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • CHD 66.84
  • Support Level
  • PBMWW N/A
  • CHD $106.63
  • Resistance Level
  • PBMWW N/A
  • CHD $108.68
  • Average True Range (ATR)
  • PBMWW 0.00
  • CHD 2.02
  • MACD
  • PBMWW 0.00
  • CHD 0.65
  • Stochastic Oscillator
  • PBMWW 0.00
  • CHD 95.15

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: